Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

Heinz Wiendl; Dennis Bourdette; Olga Ciccarelli

doi:10.1212/WNL.0000000000004381

Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

Heinz Wiendl
, Dennis Bourdette
, Olga Ciccarelli

Neurology

Research output: Contribution to journal › Editorial › peer-review

16 Scopus citations

Original language	English (US)
Pages (from-to)	1098-1100
Number of pages	3
Journal	Neurology
Volume	89
Issue number	11
DOIs	https://doi.org/10.1212/WNL.0000000000004381
State	Published - Sep 1 2017

Funding

H.W.’s work is supported by the German Research Foundation (DFG) and the Ministry of Education and Research (BMBF, the German Competence Network MK, KKNMS). D.B. receives research funding from the U.S. National MS Society. O.C. receives funding from UK MS Society and Rosetree Trust and her work is supported by NIHR UCLH BRC.

Funders
German Dementia Competence Network
UCLH NIHR
National Multiple Sclerosis Society
Deutsche Forschungsgemeinschaft
Bundesministerium für Bildung und Forschung

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0000000000004381

Cite this

@article{56ac09826caf4e2d910a30556ebf07cd,

title = "Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?",

author = "Heinz Wiendl and Dennis Bourdette and Olga Ciccarelli",

note = "Funding Information: H.W.{\textquoteright}s work is supported by the German Research Foundation (DFG) and the Ministry of Education and Research (BMBF, the German Competence Network MK, KKNMS). D.B. receives research funding from the U.S. National MS Society. O.C. receives funding from UK MS Society and Rosetree Trust and her work is supported by NIHR UCLH BRC.",

year = "2017",

month = sep,

day = "1",

doi = "10.1212/WNL.0000000000004381",

language = "English (US)",

volume = "89",

pages = "1098--1100",

journal = "Neurology",

issn = "0028-3878",